Molecular mechanisms, current management and next generation therapy in myeloma bone disease

Autor: Frédéric Baron, Arnold Bolomsky, Elodie Duray, Jo Caers, Roy Heusschen, Joséphine Muller, Heinz Ludwig, Yves Beguin, Nadia Withofs, Eline Menu
Přispěvatelé: Basic (bio-) Medical Sciences, Faculty of Medicine and Pharmacy
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
Cancer Research
Pathology
Bone disease
Multiple Myeloma/complications
Drug Evaluation
Preclinical
Osteoclasts
Signal transduction
Bone remodeling
0302 clinical medicine
Bone Marrow
Osteogenesis
novel therapies
Bone Diseases/diagnosis
Diphosphonates/pharmacology
Multiple myeloma
Clinical Trials as Topic
Bone Density Conservation Agents
Diphosphonates
Disease Management
Bone Marrow/drug effects
Osteoblast
Bisphosphonates
Hematology
Bone Resorption/drug therapy
Osteogenesis/drug effects
multiple myeloma
Treatment Outcome
medicine.anatomical_structure
030220 oncology & carcinogenesis
Bone Remodeling
Bone Diseases
TUMOR MICROENVIRONMENT
medicine.medical_specialty
Bone resorption
Osteoblasts/drug effects
03 medical and health sciences
Osteoclast
Internal medicine
medicine
Humans
Animals
Bone Resorption
Bone Density Conservation Agents/pharmacology
clinical trials
Osteoblasts
business.industry
medicine.disease
030104 developmental biology
bone disease
Osteoclasts/drug effects
Bone marrow
business
Zdroj: Leukemia & Lymphoma. 59:14-28
ISSN: 1029-2403
1042-8194
DOI: 10.1080/10428194.2017.1323272
Popis: Multiple myeloma (MM) bone disease is a major cause of morbidity and mortality in MM patients and persists even in patients in remission. This bone disease is caused by an uncoupling of bone remodeling, with increased osteoclast and decreased osteoblast activity and formation, culminating in lytic bone destruction. Bisphosphonates are the current standard of care but new therapies are needed. As the molecular mechanisms controlling MM bone disease are increasingly well understood, new therapeutic targets are extensively explored in the preclinical setting and initial clinical trials with novel compounds now show promising results. In this review, we will provide a comprehensive overview of the biology of MM bone disease, summarize its current clinical management and discuss preclinical and clinical data on next generation therapies.
Databáze: OpenAIRE
Externí odkaz: